A randomised, placebo controlled, double blind, cross-over, single center clinical Study to investigate the effect of heart rate reduction with ivabradine on endothelial function and vascular stiffness in patients with stable coronary heart disease

Trial Profile

A randomised, placebo controlled, double blind, cross-over, single center clinical Study to investigate the effect of heart rate reduction with ivabradine on endothelial function and vascular stiffness in patients with stable coronary heart disease

Recruiting
Phase of Trial: Phase IV

Latest Information Update: 27 Feb 2017

At a glance

  • Drugs Ivabradine (Primary)
  • Indications Angina pectoris; Coronary artery disease; Coronary disorders
  • Focus Therapeutic Use
  • Most Recent Events

    • 14 Jan 2013 Additional lead trial centres identified as reported by ClinicalTrials.gov.
    • 14 Jan 2013 Planned End Date changed from 17 Sep 2014 to 1 Dec 2014 as reported by ClinicalTrials.gov.
    • 25 Sep 2012 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top